Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022
About Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease is a condition in which excess fat is stored in the liver. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver cell damage.
Technavio’s analysts forecast the Global Non-alcoholic Fatty Liver Disease Therapeutics Market to grow at a CAGR of 16.19% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the non-alcoholic fatty liver disease therapeutics market. To calculate the market size, the report considers the revenue generated by the applications of non-alcoholic fatty liver disease therapeutics across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global non-alcoholic fatty liver disease therapeutics market: ALLERGAN, GlaxoSmithKline, Merck, Novartis, and Pfizer.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the growing number of strategic alliances. Vendors in the global non-alcoholic fatty liver disease therapeutics market are regularly engaging in strategic alliances to consolidate their market position.”
According to the report, one driver influencing this market is the increasing prevalence of non-alcoholic fatty liver disease. The global non-alcoholic fatty liver disease therapeutics is expected to grow during the forecast period owing to growing incidences of non-alcoholic fatty liver diseases across the globe.
Further, the report states that one challenge affecting this market is the unclear pathogenesis of non-alcoholic fatty liver disease. One of the main drawbacks of the assessment and treatment of non-alcoholic fatty liver disease is the lack of accurate noninvasive diagnostic methods.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook